Evidence map›Paper›PMID 36295795›Full record

ArticleMetabolites2022

Clinical and Metabolic Characteristics of Hyperuricemia with Risk of Liver Fibrosis: A Cross-Sectional Study.

Chun-Yi Wang, Hsiang-Han Kao, Kuan-Yu Lai, Ching-Chun Lin, Wen-Yuan Lin, Chiu-Shong Liu, Tsung-Po Chen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Metabolites, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Chun-Yi WangDepartment of Community and Family Medicine, China Medical University Hospital, Taichung 404, Taiwan.
Hsiang-Han KaoDepartment of Community and Family Medicine, China Medical University Hospital, Taichung 404, Taiwan.
Kuan-Yu LaiDepartment of Community and Family Medicine, China Medical University Hospital, Taichung 404, Taiwan.
Ching-Chun LinDepartment of Community and Family Medicine, China Medical University Hospital, Taichung 404, Taiwan.
Wen-Yuan LinDepartment of Community and Family Medicine, China Medical University Hospital, Taichung 404, Taiwan.
Chiu-Shong LiuDepartment of Community and Family Medicine, China Medical University Hospital, Taichung 404, Taiwan.
Tsung-Po ChenDepartment of Community and Family Medicine, China Medical University Hospital, Taichung 404, Taiwan.ORCID 0000-0002-8016-2573
China Medical University · TW

Funding

China Medical University Hospital DMR-111-242
6 · The paper itself

Abstract

The role of serum uric acid (SUA) in the role of advanced fibrosis is not fully explored. The study assesses the risk of advanced fibrosis according to SUA in an Asian population with a total of 3612 subjects enrolled in one health management center between 2006 and 2008. The fibrosis-4 score was used for the prediction of the high risk of advanced fibrosis. SUA scores higher than 7.6 mg/dL in men and 6.6 mg/dL in women were defined as hyperuricemia. A proportional odds model was used to assess cumulative risks of advanced fibrosis. The prevalence of high risk of advanced fibrosis was 2.5% in the hyperuricemia group and 0.6% in the normal SUA group (p < 0.001). After adjustment for confounding factors, the odds ratios (OR) for more severe advanced fibrosis were 1.37 (95% confidence interval [CI]: 1.07−1.78) in the hyperuricemia group. Hyperuricemia only increased the risk of advanced fibrosis in the non-T2DM group (OR, 1.29; 95% CI, 1.04 to 1.74) instead of T2DM group (OR, 1.85; 95% CI, 0.97 to 3.53). SUA is a risk factor for a higher risk of advanced fibrosis, with the disease likely progressing from a steatotic to a fibrotic picture. The focus should be more emphasized in non-T2DM groups.

Indexed as

advanced fibrosishyperuricemianon-alcoholic fatty liver diseasetype 2 diabetes

Identifiers

PMID36295795
PMCPMC9607284
OpenAlexW4297008553

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.